| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 DJ Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, ... New England journal of medicine 344 (11), 783-792, 2001 | 14021 | 2001 |
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer MJ Piccart-Gebhart, M Procter, B Leyland-Jones, A Goldhirsch, M Untch, ... New England Journal of Medicine 353 (16), 1659-1672, 2005 | 6562 | 2005 |
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck JA Bonner, PM Harari, J Giralt, N Azarnia, DM Shin, RB Cohen, CU Jones, ... New England Journal of Medicine 354 (6), 567-578, 2006 | 6422 | 2006 |
| Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ... The Lancet 384 (9938), 164-172, 2014 | 4285 | 2014 |
| The landscape of somatic copy-number alteration across human cancers R Beroukhim, CH Mermel, D Porter, G Wei, S Raychaudhuri, J Donovan, ... Nature 463 (7283), 899-905, 2010 | 4190 | 2010 |
| Trastuzumab emtansine for HER2-positive advanced breast cancer S Verma, D Miles, L Gianni, IE Krop, M Welslau, J Baselga, M Pegram, ... New England journal of medicine 367 (19), 1783-1791, 2012 | 4091 | 2012 |
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer M Fukuoka, S Yano, G Giaccone, T Tamura, K Nakagawa, JY Douillard, ... Journal of clinical oncology 21 (12), 2237-2246, 2003 | 3950 | 2003 |
| Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer J Baselga, M Campone, M Piccart, HA Burris III, HS Rugo, T Sahmoud, ... New England Journal of Medicine 366 (6), 520-529, 2012 | 3394 | 2012 |
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer J Baselga, J Cortés, SB Kim, SA Im, R Hegg, YH Im, L Roman, JL Pedrini, ... New England Journal of Medicine 366 (2), 109-119, 2012 | 3089 | 2012 |
| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3074 | 2019 |
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt KE O'Reilly, F Rojo, QB She, D Solit, GB Mills, D Smith, H Lane, ... Cancer research 66 (3), 1500-1508, 2006 | 2977 | 2006 |
| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 2917 | 2017 |
| Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition M Yu, A Bardia, BS Wittner, SL Stott, ME Smas, DT Ting, SJ Isakoff, ... science 339 (6119), 580-584, 2013 | 2644 | 2013 |
| Systematic identification of genomic markers of drug sensitivity in cancer cells MJ Garnett, EJ Edelman, SJ Heidorn, CD Greenman, A Dastur, KW Lau, ... Nature 483 (7391), 570-575, 2012 | 2541 | 2012 |
| Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash … JA Bonner, PM Harari, J Giralt, RB Cohen, CU Jones, RK Sur, D Raben, ... The lancet oncology 11 (1), 21-28, 2010 | 2429 | 2010 |
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer SM Swain, J Baselga, SB Kim, J Ro, V Semiglazov, M Campone, ... New England journal of medicine 372 (8), 724-734, 2015 | 2292 | 2015 |
| Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2229 | 2015 |
| Genomic analysis identifies association of Fusobacterium with colorectal carcinoma AD Kostic, D Gevers, CS Pedamallu, M Michaud, F Duke, AM Earl, ... Genome research 22 (2), 292-298, 2012 | 2013 | 2012 |
| Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Baselga, D Tripathy, J Mendelsohn, S Baughman, CC Benz, L Dantis, ... Journal of clinical oncology 14 (3), 737-744, 1996 | 1963 | 1996 |
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial I Smith, M Procter, RD Gelber, S Guillaume, A Feyereislova, M Dowsett, ... The lancet 369 (9555), 29-36, 2007 | 1955 | 2007 |
